{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:50:23Z","timestamp":1790736623949,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.hoc.2025.04.019","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:30:48Z","timestamp":1761766248000},"page":"1057-1075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging Therapeutic Targets for Platinum-Resistant Ovarian Cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"Connor C.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gomez-Roas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Hinchcliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.hoc.2025.04.019_bib2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ygyno.2015.06.017","article-title":"Why have ovarian cancer mortality rates declined? Part I. Incidence","volume":"138","author":"Sopik","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.04.019_bib3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.019_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.019_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2025.04.019_bib6","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1080\/00016340802495491","article-title":"Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up","volume":"87","author":"\u00c5keson","year":"2008","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"10.1016\/j.hoc.2025.04.019_bib7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.04.019_bib8","article-title":"Ovarian cancer\u2014insights into platinum resistance and overcoming it","volume":"59","author":"Havasi","year":"2023","journal-title":"Medicina (Lithuania)"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.019_bib9","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2025.04.019_bib10","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2025.04.019_bib11","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.019_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.23.01771","article-title":"Treatment approaches for platinum-resistant ovarian cancer","volume":"42","author":"Laurent","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104434","article-title":"Clinical and molecular features of platinum resistance in ovarian cancer","volume":"201","author":"Miras","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"10.1016\/j.hoc.2025.04.019_bib14","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.04.019_bib15","article-title":"Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (Review)","volume":"47","author":"Mai","year":"2022","journal-title":"Oncol Rep"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.019_bib16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"issue":"10271","key":"10.1016\/j.hoc.2025.04.019_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2025.04.019_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2020.08.013","article-title":"New approaches for targeting platinum-resistant ovarian cancer","volume":"77","author":"McMullen","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"27","key":"10.1016\/j.hoc.2025.04.019_bib19","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.04.019_bib20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.20517\/cdr.2022.13","article-title":"Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer","author":"Flynn","year":"2022","journal-title":"Cancer Drug Resistance"},{"issue":"14","key":"10.1016\/j.hoc.2025.04.019_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19148577","article-title":"Recent insights into PARP and immuno-checkpoint inhibitors in epithelial ovarian cancer","volume":"19","author":"Revythis","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"25","key":"10.1016\/j.hoc.2025.04.019_bib23","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2025.04.019_bib24","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2025.04.019_bib25","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.019_bib26","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.019_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2025.04.019_bib28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","article-title":"Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers","volume":"74","author":"Karst","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2025.04.019_bib29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2023.05.063","article-title":"WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: a biomarker-enriched phase II study","volume":"174","author":"Embaby","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semcancer.2020.10.016","article-title":"Genomic profiling of platinum-resistant ovarian cancer: the road into druggable targets","volume":"77","author":"da Costa","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.hoc.2025.04.019_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1258228","article-title":"Overcoming the challenges of drug development in platinum-resistant ovarian cancer","volume":"13","author":"Eskander","year":"2023","journal-title":"Front Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2025.04.019_bib32","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3747\/co.2007.148","article-title":"Optimal chemotherapy treatment for women with recurrent ovarian cancer","volume":"14","author":"Fung-Kee-Fung","year":"2007","journal-title":"Curr Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2025.04.019_bib34","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1002\/cncr.30830","article-title":"Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: myth or reality?","volume":"123","author":"Tomao","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2025.04.019_bib35","first-page":"7147","article-title":"Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature","volume":"30","author":"Pergialiotis","year":"2022","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2025.04.019_bib36","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.019_bib37","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.hoc.2018.07.007","article-title":"Mechanisms of drug resistance in high-grade serous ovarian cancer","volume":"32","author":"Freimund","year":"2018","journal-title":"Hematol Oncol Clin N Am"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.019_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020448","article-title":"DNA damage response alterations in ovarian cancer: from molecular mechanisms to therapeutic opportunities","volume":"15","author":"Ovejero-S\u00e1nchez","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.019_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.019_bib40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","article-title":"Pathogenesis and heterogeneity of ovarian cancer","volume":"29","author":"Kroeger","year":"2017","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.019_bib41","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2018.07.006","article-title":"Targeting DNA damage response and repair as a therapeutic strategy for ovarian cancer","volume":"32","author":"Konstantinopoulos","year":"2018","journal-title":"Hematol Oncol Clin N Am"},{"issue":"16","key":"10.1016\/j.hoc.2025.04.019_bib42","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2025.04.019_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2023.10.005","article-title":"Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE\/GOG-3032)","volume":"178","author":"Randall","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.019_bib44","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0090-8258(22)01244-6","article-title":"Final overall survival results from SOLO3: phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and\/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026)","volume":"166","author":"Penson","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib45","doi-asserted-by":"crossref","first-page":"S780","DOI":"10.1016\/j.annonc.2022.07.646","article-title":"518O Overall survival results from ARIEL4: a phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1\/2 mutation","volume":"33","author":"Oza","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.04.019_bib46","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01934","article-title":"Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update","author":"Tew","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.019_bib48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP Inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2025.04.019_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235902","article-title":"ATR inhibitors in platinum-resistant ovarian cancer","volume":"14","author":"Li","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hoc.2025.04.019_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106162","article-title":"Cell cycle checkpoints and beyond: exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor\u2013resistant cancer","volume":"178","author":"Gupta","year":"2022","journal-title":"Pharmacol Res"},{"issue":"7","key":"10.1016\/j.hoc.2025.04.019_bib51","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.04.019_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10050279","article-title":"CCNE1 amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer","volume":"10","author":"Gorski","year":"2020","journal-title":"Diagnostics"},{"issue":"9","key":"10.1016\/j.hoc.2025.04.019_bib53","article-title":"CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models","volume":"2","author":"Xu","year":"2021","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.hoc.2025.04.019_bib54","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-19-1638","article-title":"A randomized phase II trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer","volume":"26","author":"Oza","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2025.04.019_bib55","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1078-0432.CCR-17-3055","article-title":"A phase i clinical trial of guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer: clinical, pharmacokinetic, and pharmacodynamic analyses","volume":"24","author":"Matei","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2025.04.019_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.03.001","article-title":"ABC transporters as mediators of drug resistance and contributors to cancer cell biology","volume":"26","author":"Fletcher","year":"2016","journal-title":"Drug Resist Updates"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.019_bib57","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.critrevonc.2015.05.012","article-title":"The role of ABC transporters in ovarian cancer progression and chemoresistance","volume":"96","author":"Ween","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.hoc.2025.04.019_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2023.112324","article-title":"The mechanism of copper transporters in ovarian cancer cells and the prospect of cuproptosis","volume":"247","author":"Guo","year":"2023","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.hoc.2025.04.019_bib59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.semcancer.2021.03.031","article-title":"Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer","volume":"77","author":"El Bairi","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.hoc.2025.04.019_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102489","article-title":"Targeting NaPi2b in ovarian cancer","volume":"112","author":"Banerjee","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"10.1016\/j.hoc.2025.04.019_bib61","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.019_bib62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00280-023-04575-y","article-title":"Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations","volume":"93","author":"Nwabufo","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2025.04.019_bib63","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib64","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","article-title":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)\u2013targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer","volume":"185","author":"Richardson","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2025.04.019_bib66","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase i expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.04.019_bib67","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/ijgc-2023-004924","article-title":"Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer","volume":"34","author":"Bogani","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.019_bib68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.019_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-023-01166-0","article-title":"Antibody-drug conjugates in gynecologic cancers","volume":"25","author":"Anastasio","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.019_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.019_bib71","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s43018-022-00360-7","article-title":"Phosphate dysregulation via the XPR1\u2013KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer","volume":"3","author":"Bondeson","year":"2022","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.019_bib72","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O\u2019Malley","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2025.04.019_bib73","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/pharmaceutics16091146","article-title":"Synergizing immunotherapy and antibody\u2013drug conjugates: new horizons in breast cancer therapy","volume":"16","author":"Pinto","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.hoc.2025.04.019_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib75","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/jamaoncol.2022.2253","article-title":"Effect of apatinib plus pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: the APPROVE randomized clinical trial","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib76","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.semcancer.2020.08.017","article-title":"Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer","volume":"77","author":"Le Saux","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.019_bib77","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1200\/JCO.22.02915","article-title":"Ofranergene obadenovec (Ofra-Vec, VB-111) with weekly paclitaxel for platinum-resistant ovarian cancer: randomized controlled phase III trial (OVAL study\/GOG 3018)","volume":"42","author":"Arend","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.019_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188361","article-title":"Targeting tumor microenvironment in ovarian cancer: premise and promise","volume":"1873","author":"Jiang","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.hoc.2025.04.019_bib79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2021.02.007","article-title":"Targeting the tumour microenvironment in platinum-resistant ovarian cancer","volume":"77","author":"Cummings","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.hoc.2025.04.019_bib80","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.semcancer.2022.03.027","article-title":"Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment","volume":"86","author":"Schoutrop","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"10.1016\/j.hoc.2025.04.019_bib81","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(21)00303-X","article-title":"Immunotherapy in ovarian cancer: we are not there yet","volume":"22","author":"Barber","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.019_bib82","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2020.05.681","article-title":"Immunotherapy for platinum-resistant ovarian cancer","volume":"158","author":"Bogani","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"34","key":"10.1016\/j.hoc.2025.04.019_bib83","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib84","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.04.019_bib85","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.04.019_bib86","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.04.019_bib87","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.04.019_bib88","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hoc.2025.04.019_bib89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biocel.2018.11.012","article-title":"Ovarian cancer stem cells and their role in drug resistance","volume":"106","author":"Pieterse","year":"2019","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.019_bib90","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1634\/theoncologist.2019-0517","article-title":"The clinical impact of cancer stem cells","volume":"25","author":"Lathia","year":"2020","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.019_bib91","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-019-0588-z","article-title":"Ovarian cancer stem cells and targeted therapy","volume":"12","author":"Keyvani","year":"2019","journal-title":"J Ovarian Res"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.019_bib92","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-023-03244-4","article-title":"Targeting ovarian cancer stem cells: a new way out","volume":"14","author":"Ma","year":"2023","journal-title":"Stem Cell Res Ther"},{"issue":"11","key":"10.1016\/j.hoc.2025.04.019_bib93","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/15592294.2020.1853402","article-title":"Methylomic signatures of high grade serous ovarian cancer","volume":"16","author":"Cardenas","year":"2021","journal-title":"Epigenetics"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:02:24Z","timestamp":1761840144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0889858825000577"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.04.019","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Therapeutic Targets for Platinum-Resistant Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}